2022-11-15T08:25:09-06:00 2021-12-31 390859910 BAKER TILLY US LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2021-01-01 222473000 INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES INC INTE 6172770551 9 BABCOCK STREET UNIT 3 BROOKLINE MA 02446 LINDA MACKINNON CEO 6172770551 2022-11-14 1 LINDA MACKINNON 999009999 MATTHEW KALIL CPA MBA P01517069 9785575300 2022-11-14 X 0 AAL1 IAL1 2021 2022-09-23 18:48:47Z LINDA MACKINNON 9 BABCOCK STREET UNIT 3 BROOKLINE MA 02446 3261648 0 X WWW.ISID.ORG X 1983 MA EDUCATION PERTAINING TO INFECTIOUS DISEASES. 10 10 12 0 0 0 2919994 1294679 0 0 378668 341429 0 559817 3298662 2195925 84000 16000 0 0 901293 1180149 0 0 128369 1946646 2080879 2931939 3277028 366723 -1081103 5661861 4197503 1272490 1049167 4389371 3148336 X THE MISSION OF INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES IS TO SUPPORT HEALTH PROFESSIONALS, NON-GOVERNMENT ORGANIZATIONS, AND GOVERNMENTS AROUND THE WORLD IN THEIR WORK TO PREVENT, INVESTIGATE AND MANAGE INFECTIOUS DISEASE OUTBREAKS WHEN THEY OCCUR, PARTICULARLY IN COUNTRIES THAT HAVE LIMITED RESOURCES AND WHICH DISPROPORTIONATELY BEAR THE BURDEN OF INFECTIOUS DISEASES. 0 0 2480134 16000 559817 TO INCREASE KNOWLEDGE BASE OF INFECTIOUS DISEASE THROUGH RESEARCH AND TRAINING AND TO ENHANCE PROFESSIONAL DEVELOPMENT OF INDIVIDUALS IN THIS DISCIPLINE. SCIENTIFIC EXCHANGE FELLOWSHIP PROGRAM IS INTENDED TO ALLOW SCIENTISTS FROM DEVELOPING COUNTRIES TO UPDATE THEIR KNOWLEDGE OF NEW TECHNIQUES AND SKILLS IN THE FIELD OF INFECTIOUS DISEASES. THE SMALL GRANTS PROGRAM IS INTENDED TO FOSTER DEVELOPMENT OF YOUNG INFECTIOUS DISEASE PROFESSIONALS IN THE DEVELOPING WORLD. 2480134 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 31 0 12 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X THE ORGANIZATION 6172770551 9 BABCOCK STREET UNIT 3 BROOKLINE MA 02446 ZAMBERI SEKAWI BOARD MEMBER 1.00 X 0 0 0 URSULA THEURETZBACHER BOARD MEMBER 1.00 X 0 0 0 MIGUEL O'RYAN BOARD MEMBER 1.00 X 0 0 0 ROBERT HEYDERMAN BOARD MEMBER 1.00 X 0 0 0 NEELIKA MALAVIGE BOARD MEMBER 1.00 X 0 0 0 GAGANDEEP KANG BOARD MEMBER 1.00 X 0 0 0 SALLY ROBERTS TREASURER 2.00 X 0 0 0 MARC MENDELSON PAST PRESIDENT 1.00 X 0 0 0 PAUL TAMBYAH PRESIDENT ELECT 1.00 X X 0 0 0 ALLISON HOLMES PRESIDENT 5.00 X X 0 0 0 LINDA MACKINNON CEO 40.00 X 193851 0 20698 BRITTA LASSMAN PROGRAM DIRECTOR 25.00 X 118770 0 14014 ANDREW DALECKI CFO (SINCE MAY 2021) 40.00 X 117933 0 5487 CATHERINE CROWLEY DIRECTOR OF BUSINESS DEVELOPMENT 40.00 X 105872 0 13553 536426 0 53752 4 0 1 0 BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 PROMED RELATED RESEARCH COLLABORATION 223700 IMPERIAL COLLEGE LONDON LEVEL 3 SHERFIELD BLDG SOUTH KENSI LONDON SW AZ ENGLAND UK PROMED RELATED RESEARCH COLLABORATION 107228 2 159509 1135170 1294679 72775 72775 559817 559817 1334377 1065723 268654 268654 268654 2195925 559817 0 341429 X 16000 16000 470753 288490 117898 64365 515150 443203 28196 43751 43854 34807 6034 3013 77357 59984 9203 8170 73035 54522 10643 7870 70134 70134 24148 24148 25230 25230 1591557 1387311 203046 1200 61932 29177 32755 33342 5280 28062 61045 40879 20166 11616 11616 12124 12124 26442 26442 17457 17457 EVENT COSTS 114085 113711 374 OTHER EXPENSES 20899 3077 17822 TRAINING 10868 3693 7175 3277028 2480134 668525 128369 260381 210000 137431 1356947 992527 615619 725916 1889 5222 703938 312493 411519 391445 2878075 1872393 5661861 4197503 572535 531833 540446 517334 159509 0 1272490 1049167 X 1904983 1589510 2484388 1558826 4389371 3148336 5661861 4197503 X -1081103 -166061 6129 X X 0 1 X 1 0 X 1475209 1934428 2819213 2294122 1294679 9817651 1475209 1934428 2819213 2294122 1294679 9817651 3152026 6665625 80104 240284 235693 710565 632592 1899238 11716889 0.56890 0.51160 X SCHEDULE A, PART II, SECTION A, COLUMN D, LINE 1: THE PRIOR YEAR AMOUNT FOR 2020 ON LINE 1 HAS BEEN RESTATED TO OMIT ROYALTIES OF $625,872. ROYALTIES HAVE BEEN ADDED TO SECTION B, COLUMN D, LINE 8. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 611834 236377 375457 68450 56765 11685 23654 19351 4303 391445 X 2010763 -166061 6129 -159932 2170695 25230 25230 2195925 3251798 0 3251798 25230 25230 3277028 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON TRADE OR BUSINESS PROFITS GENERATED BY ACTIVITIES RELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM TRADE OR BUSINESS ACTIVITIES UNRELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. AS OF DECEMBER 31, 2021, MANAGEMENT BELIEVES THAT THE ORGANIZATION HAS NOT GENERATED ANY UNRELATED BUSINESS TAXABLE INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE FINANCIAL STATEMENTS. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ACCRUED ON ANY UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSE, IF ANY, IN ITS STATEMENTS OF ACTIVITIES. THE ORGANIZATION HAS NOT RECOGNIZED ANY LIABILITIES FOR UNCERTAIN TAX POSITIONS OR UNRECOGNIZED BENEFITS AS OF DECEMBER 31, 2021. THE ORGANIZATION DOES NOT EXPECT ANY MATERIAL CHANGE IN UNCERTAIN TAX BENEFITS WITHIN THE NEXT 12 MONTHS. PART XI, LINE 2D - OTHER ADJUSTMENTS: GAIN ON FOREIGN CURRENCY EXCHANGE 6,129. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANT TO 1 RESEARCHER IN THE FIELD OF INFECTIOUS DISEASES. FELLOWSHIP/GRANT PROGRAM 4000 SOUTH ASIA 0 0 GRANT TO 1 RESEARCHER IN THE FIELD OF INFECTIOUS DISEASES. FELLOWSHIP/GRANT PROGRAM 8000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANT TO 1 RESEARCHER IN THE FIELD OF INFECTIOUS DISEASES. FELLOWSHIP/GRANT PROGRAM 4000 0 0 0 0 0 0 16000 0 16000 RESEARCH GRANT FOR INFECTIOUS DISEASES CENTRAL AMERICA AND THE CARIBBEAN 1 4000 WIRE TRANSFER 0 RESEARCH GRANT FOR INFECTIOUS DISEASES SOUTH ASIA 1 8000 WIRE TRANSFER 0 RESEARCH GRANT FOR INFECTIOUS DISEASES EUROPE (INCLUDING ICELAND & GREENLAND) 1 4000 WIRE TRANSFER 0 0 0 0 0 0 0 PART I, LINE 2: A WRITTEN REPORT OF THE PROJECT IS REQUIRED FROM GRANT RECIPIENTS. THE REPORT MUST BE SENT TO INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES AND RECIPIENTS ARE ENCOURAGED TO PRESENT THEIR FINDINGS AT SCIENTIFIC MEETINGS OR IN PEER REVIEWED PUBLICATIONS. PART III ACCOUNTING METHOD: X X 0 0 0 0 0 0 0 0 0 LINDA MACKINNON CEO 193851 0 0 0 0 0 13570 0 7128 0 214549 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND THEN REVIEWED BY THE DIRECTOR OF FINANCE AND THE EXECUTIVE DIRECTOR. THE 990 IS THEN MADE AVAILABLE TO THE BOARD OF DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS ARE REQUIRED TO COMPLETE A CONFLICT OF INTEREST STATEMENT THAT DISCLOSES ANY CONFLICT OF INTERESTS THEY MAY HAVE. ALL CONFLICTS ARE TO BE DECLARED AT THE BEGINNING OF EACH COMMITTEE MEETING AND DISCUSSED ACCORDINGLY. FORM 990, PART VI, SECTION B, LINE 15 SALARY LEVELS ARE BASED ON EVALUATION OF FACTORS INCLUDING, BUT NOT LIMITED TO; THE AMOUNT AND SCOPE OF KNOWLEDGE, TRAINING AND/OR SPECIALIZED SKILLS REQUIRED; SCOPE AND RANGE OF RESPONSIBILITIES OF THE POSITION; THE ORGANIZATIONAL AUTHORITY; LEVEL OF SUPERVISION EXERCISED; THE SCOPE AND TYPE OF INTERACTION WITH OTHER EMPLOYEES, MEMBERS, BOARD AND COMMITTEE MEMBERS, PEERS IN OTHER ORGANIZATIONS, VENDORS, PROFESSIONAL PARTNERS; AND BASED ON COMPARATIVE INDUSTRY BENCHMARKS. SALARY LEVELS ARE APPROVED BY THE EXECUTIVE COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 1,387,311. MANAGEMENT AND GENERAL EXPENSES 203,046. FUNDRAISING EXPENSES 1,200. TOTAL EXPENSES 1,591,557. FORM 990, PART XI, LINE 9: GAIN ON FOREIGN CURRENCY EXCHANGE 6,129. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT FOR THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED DURING THE YEAR.